{"id":"aezs-130-formerly-ard-07","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AEZS-130 binds to the androgen receptor and prevents activation by androgens, thereby inhibiting growth of androgen-dependent cancer cells. It is designed to have improved tissue selectivity and potentially overcome resistance mechanisms seen with earlier-generation AR antagonists. The drug targets the AR signaling pathway, which is central to the progression of castration-resistant prostate cancer and other hormone-sensitive malignancies.","oneSentence":"AEZS-130 is a selective androgen receptor (AR) antagonist that blocks androgen signaling in hormone-sensitive cancers.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:11.281Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Castration-resistant prostate cancer (CRPC)"},{"name":"Hormone-sensitive prostate cancer"}]},"trialDetails":[{"nctId":"NCT00448747","phase":"PHASE3","title":"Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.","status":"COMPLETED","sponsor":"AEterna Zentaris","startDate":"2007-06","conditions":"Diagnosis of Adult Growth Hormone Deficiency (AGDH)","enrollment":101}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Test 1","Macimorelin"],"phase":"phase_3","status":"active","brandName":"AEZS-130 (formerly ARD-07)","genericName":"AEZS-130 (formerly ARD-07)","companyName":"AEterna Zentaris","companyId":"aeterna-zentaris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AEZS-130 is a selective androgen receptor (AR) antagonist that blocks androgen signaling in hormone-sensitive cancers. Used for Castration-resistant prostate cancer (CRPC), Hormone-sensitive prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}